Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $70.00 Price Target at Morgan Stanley

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Several other equities research analysts have also recently commented on CRNX. Jonestrading increased their price objective on Crinetics Pharmaceuticals […]

Related Keywords

Arizona ,United States ,Texas ,Robertw Baird ,Dana Pizzuti ,Richard Scott Struthers ,Analyst Recommendations For Crinetics Pharmaceuticals ,Cantor Fitzgerald ,Principal Financial Group Inc ,Securities Exchange Commission ,News Ratings For Crinetics Pharmaceuticals Daily ,Morgan Stanley ,Nasdaq ,Citigroup ,Mirae Asset Global Investments Co ,Crinetics Pharmaceuticals ,Crinetics Pharmaceuticals Stock Performance ,Victory Capital Management Inc ,Crinetics Pharmaceuticals Inc ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Scott Struthers ,Asset Global Investments ,Retirement System ,Financial Group ,Capital Management ,Arizona State Retirement System ,State Retirement System ,Crinetics Pharmaceuticals Daily ,